{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:03:48Z","timestamp":1791417828754,"version":"4.3.3"},"reference-count":70,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Background: In recent decades, several viruses have jumped from animals to humans, triggering sizable outbreaks. The current unprecedent outbreak SARS-COV-2 is prompting a search for new cost-effective therapies to combat this deadly pathogen. Suitably functionalized polysubstituted quinoxalines show very interesting biological properties (antiviral, anticancer, and antileishmanial), ensuring them a bright future in medicinal chemistry. Objectives: Focusing on the promising development of new quinoxaline derivatives as antiviral drugs, this review forms part of our program on the anti-infectious activity of quinoxaline derivatives. Methods: Study compiles and discusses recently published studies concerning the therapeutic potential of the antiviral activity of quinoxaline derivatives, covering the literature between 2010 and 2020. Results: A final total of 20 studies included in this review. Conclusions: This review points to a growing interest in the development of compounds bearing a quinoxaline moiety for antiviral treatment. This promising moiety with different molecular targets warrants further investigation, which may well yield even more encouraging results regarding this scaffold.<\/jats:p>","DOI":"10.3390\/molecules25122784","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T12:21:46Z","timestamp":1592482906000},"page":"2784","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Quinoxaline Derivatives as Antiviral Agents: A Systematic Review"],"prefix":"10.3390","volume":"25","author":[{"given":"Marc","family":"Montana","sequence":"first","affiliation":[{"name":"Laboratoire de Pharmaco-Chimie Radicalaire, Institut de Chimie Radicalaire ICR, Aix Marseille Univ, CNRS, UMR 7273, 13005 Marseille, France"},{"name":"Oncopharma, H\u00f4pital Nord, Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Montero","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmaco-Chimie Radicalaire, Institut de Chimie Radicalaire ICR, Aix Marseille Univ, CNRS, UMR 7273, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Khoumeri","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmaco-Chimie Radicalaire, Institut de Chimie Radicalaire ICR, Aix Marseille Univ, CNRS, UMR 7273, 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Vanelle","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmaco-Chimie Radicalaire, Institut de Chimie Radicalaire ICR, Aix Marseille Univ, CNRS, UMR 7273, 13005 Marseille, France"},{"name":"Service central de la qualit\u00e9 et de l\u2019information pharmaceutiques (SCQIP), Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), 13005 Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.7665.1","article-title":"Current Landscape of Antiviral Drug Discovery","volume":"5","author":"Blair","year":"2016","journal-title":"F1000Research"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1016\/j.bmcl.2016.06.053","article-title":"Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress","volume":"26","author":"Loughran","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/HMER.S62014","article-title":"Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: From the clinical trials to real life","volume":"8","author":"Pol","year":"2016","journal-title":"Hepatic Med. Evid. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1039\/C7MD00097A","article-title":"An insight into the therapeutic potential of quinazoline derivatives as anticancer agents","volume":"8","author":"Shagufta","year":"2017","journal-title":"Med. Chem. Com."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2016.03.058","article-title":"Recent insight into the biological activities of the synthetic xanthone derivatives","volume":"116","author":"Shagufta","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ejmech.2015.08.010","article-title":"Recent developments in steroidal and nonsteroidal aromatase inhibitors for the chemoprevention of oestrogen-dependent breast cancer","volume":"102","author":"Ahmad","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_8","first-page":"19","article-title":"An important class of organic compounds with diverse biological activities","volume":"7","author":"Ahmad","year":"2015","journal-title":"Int. J. Pharm. Sci."},{"key":"ref_9","first-page":"33","article-title":"Biological activity of quinoxaline derivatives","volume":"2","author":"Deepika","year":"2011","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ejmech.2017.11.064","article-title":"Quinoxaline: An insight into the recent pharmacological advances","volume":"143","author":"Tariq","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","first-page":"78","article-title":"Condensed Pyrazines","volume":"Volume 35","author":"Weissberger","year":"1979","journal-title":"The Chemistry of Heterocyclic Compounds"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ejmech.2014.06.058","article-title":"Quinoxaline, its derivative and applications: A state of the art review","volume":"97","author":"Pereira","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_13","unstructured":"Brown, D.J., and Ellman, J.A. (2004). The Chemistry of Heterocyclic Compounds, Wiley."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1021\/jo060450v","article-title":"Straightforward access to pyrazines, piperazinones, and quinoxalines by reactions of 1,2-diaza-1,3-butadienes with 1,2-diamines under solution, solvent-free, or solid-phase conditions","volume":"71","author":"Aparicio","year":"2006","journal-title":"J. Org. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5155\/eurjchem.2.4.495-498.413","article-title":"An efficient synthesis of quinoxalines catalyzed by monoammonium salt of 12-tungstophosphoric acid","volume":"2","author":"Kunkuma","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1016\/S0040-4039(02)00715-3","article-title":"Direct and catalytic synthesis of quinoxaline derivatives from epoxides and ene-1,2-diamines","volume":"43","author":"Antoniotti","year":"2002","journal-title":"Tetrahedron Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.1016\/j.tetlet.2008.10.058","article-title":"Gallium triflate catalyzed synthesis of quinoxaline derivatives","volume":"49","author":"Cai","year":"2008","journal-title":"Tetrahedron Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF02711453","article-title":"One-pot efficient green synthesis of 1,4-dihydroquinoxaline-2,3-dione derivatives","volume":"118","author":"Thakuria","year":"2006","journal-title":"J. Chem. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.tetlet.2007.11.204","article-title":"Synthesis of potential chemotherapic quinoxalinone derivatives by biocatalysis or microwave-assisted Hinserg reaction","volume":"49","author":"Gris","year":"2008","journal-title":"Tetrahedron Lett."},{"key":"ref_20","first-page":"303","article-title":"The synthesis of quinoxalines under microwave irradiation Indian","volume":"10","author":"Rostamizadeh","year":"2001","journal-title":"J. Heterocycl. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00304948.2013.743419","article-title":"Recent developments in the synthesis of quinoxaline derivatives by green synthetic approaches","volume":"45","author":"Nageswar","year":"2013","journal-title":"Org. Prep. Proc. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0166-3542(91)90066-Z","article-title":"The mechanism of action of the anti-herpes virus compound 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline","volume":"15","author":"Harmenberg","year":"1991","journal-title":"Antiviral. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejmech.2018.11.059","article-title":"Antitumoral activity of quinoxaline derivatives: A systematic review","volume":"163","author":"Montana","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1016\/j.bmc.2018.06.033","article-title":"Quinoxaline derivatives as potential antitrypanosomal and antileishmanialagents","volume":"7","author":"Cogo","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1517\/13543776.2012.724677","article-title":"Quinoxaline derivatives: A patent review (2006--present)","volume":"22","author":"Cerecetto","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1128\/AAC.37.8.1659","article-title":"Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication","volume":"37","author":"Kleim","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","first-page":"123","article-title":"The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"3","author":"Moher","year":"2009","journal-title":"Open Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.bmcl.2010.01.094","article-title":"The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase","volume":"20","author":"Tanis","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1007\/s00044-011-9753-7","article-title":"[1,2,4] Triazolo [4,3-a] quinoxaline: Synthesis, antiviral, and antimicrobial activities","volume":"9","author":"Henen","year":"2012","journal-title":"Med. Chem. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/15734064113096660069","article-title":"Synthesis, antioxidant, anticancer and antiviral activities of novel quinoxaline hydrazone derivatives and their acyclic C-nucleosides","volume":"10","year":"2014","journal-title":"Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1700028","DOI":"10.1002\/ardp.201700028","article-title":"Synthesis, Characterization, and Biological Evaluation of Some Novel Quinoxaline Derivatives as Antiviral Agents","volume":"350","year":"2017","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejmech.2010.11.022","article-title":"Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives","volume":"46","author":"Galal","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.tetlet.2014.01.106","article-title":"A novel and easy two-step, microwave-assisted method for the synthesis of halophenyl pyrrolo[2,3-b]quinoxalines via their pyrrolo precursors","volume":"55","author":"Manta","year":"2014","journal-title":"Eval. Their Bioactivity Tetrahedron Lett."},{"key":"ref_34","first-page":"234","article-title":"Synthesis and novel chemical reaction for a new class of 3-(1\u2032,2\u2032-dihydroxyeth-1\u2032-yl)-1-phenylpyrazolo [3,4-b] quinoxaline series \u201cC-nucleosides\u201d as antiviral agents","volume":"9","author":"Fakhreldin","year":"2012","journal-title":"Life Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejmech.2017.12.083","article-title":"Quinoxaline derivatives as new inhibitors of coxsackievirus B5","volume":"145","author":"Carta","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/j.bmcl.2011.03.042","article-title":"Synthesis and evaluation of quinoxaline derivatives as potential influenza NS1A protein inhibitors","volume":"21","author":"You","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1016\/j.bmc.2011.10.009","article-title":"Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors","volume":"19","author":"Carta","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejmech.2015.10.002","article-title":"Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives","volume":"105","author":"Briguglio","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","article-title":"MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants","volume":"56","author":"Summa","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1074\/jbc.M116.772996","article-title":"Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3\/4A protease from genotype 1a","volume":"292","author":"Guo","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1021\/acsmedchemlett.8b00150","article-title":"Quinoxaline-Based Linear HCV NS3\/4A Protease Inhibitors Exhibit Potent Activity against Drug Resistant Variants","volume":"9","author":"Rusere","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1021\/acs.jmedchem.7b00426","article-title":"Hepatitis C Virus NS3\/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants","volume":"60","author":"Matthew","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ejmech.2010.11.040","article-title":"Synthesis and biological activity of 7H-benzo[4,5]indolo[2,3-b]-quinoxaline derivatives","volume":"46","author":"Shibinskaya","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ejmech.2009.12.014","article-title":"Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxalines","volume":"45","author":"Shibinskaya","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"111987","DOI":"10.1016\/j.ejmech.2019.111987","article-title":"Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme","volume":"188","author":"Fabian","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejmech.2016.04.019","article-title":"Design, synthesis and anti-HIV activity of novel quinoxaline derivatives","volume":"117","author":"Patel","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.bmc.2016.03.043","article-title":"Design, synthesis and anti-HIV-1 evaluation of hydrazide-based peptidomimetics as selective gelatinase inhibitors","volume":"24","author":"Yang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Nathanson, N., and Gonz\u00e1lez-Scarano, F. (2016). Patterns of infection. Viral Pathogenesis, 81\u201394.","DOI":"10.1016\/B978-0-12-800964-2.00007-0"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Ryu, W.S. (2017). Discovery and Classification. Mol. Virol. Human Pathog. Viruses, 3\u201320.","DOI":"10.1016\/B978-0-12-800838-6.00001-1"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-3-0348-8012-1_8","article-title":"Current and potential therapies for the treatment of herpes-virus infections","volume":"60","author":"Villareal","year":"2003","journal-title":"Prog. Drug Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0166-3542(01)00208-X","article-title":"Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses","volume":"54","author":"Brideau","year":"2002","journal-title":"Antiviral Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2165\/00003495-199039040-00008","article-title":"Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections","volume":"39","author":"Faulds","year":"1990","journal-title":"Drugs"},{"key":"ref_53","first-page":"5","article-title":"Drug-resistant herpes: Cidofovir gel in limbo. Interview with Jay Lalezari, M.D. Interview by John S. James","volume":"283","author":"Lalezari","year":"1997","journal-title":"AIDS Treat. News"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/toxsci\/kfh183","article-title":"The tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) provokes a prolonged morphologic response and ERK activation in Tsc2-null renal tumor cells","volume":"81","author":"Kolb","year":"2004","journal-title":"Toxicol. Sci."},{"key":"ref_55","unstructured":"Louten, J. (2016). Essential Human Virology, Elsevier, Academic Press. [1st ed.]."},{"key":"ref_56","unstructured":"Badri, T., and Gandhi, G.R. (2020, May 05). Molluscum Contagiosum. Treasure Island (FL): StatPearls Publishing, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441898\/."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1389202916666150707160613","article-title":"RNA Viruses: RNA Roles in Pathogenesis, Coreplication and Viral Load","volume":"16","author":"Poltronieri","year":"2015","journal-title":"Curr. Genomics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.3892\/mmr.2014.2578","article-title":"Coxsackievirus B detection in cases of myocarditis, myopericarditis, pericarditis and dilated cardiomyopathy in hospitalized patients","volume":"10","author":"Gaaloul","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lee, C.J., Huang, Y.C., Yang, S., Tsao, K.C., Chen, C.J., Hsieh, Y.C., Chiu, C.H., and Lin, T.Y. (2014). Clinical features of coxsackievirus A4, B3 and B4 infections in children. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087391"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1099\/vir.0.2008\/004606-0","article-title":"The multifunctional NS1 protein of influenza A viruses","volume":"89","author":"Hale","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"20584","DOI":"10.1074\/jbc.M611619200","article-title":"Conserved surface features form the double-stranded RNA binding site of non-structural protein 1 (NS1) from influenza A and B viruses","volume":"282","author":"Yin","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0602184103","article-title":"The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2\u2032-5\u2032 oligo (A) synthetase\/RNase L pathway","volume":"103","author":"Min","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_64","unstructured":"(2020, May 05). Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB), Available online: https:\/\/www.cdc.gov\/vhf\/ebola\/treatment\/index.html."},{"key":"ref_65","unstructured":"World Health Organisation (2020, May 05). Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1021\/ja711120r","article-title":"Molecular modeling-based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3\/4A protease","volume":"130","author":"Liverton","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Romano, K.P., Ali, A., Aydin, C., Soumana, D., Ozen, A., Deveau, L.M., Silver, C., Cao, H., Newton, A., and Petropoulos, C.J. (2012). The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002832"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1021\/ml400466p","article-title":"Novel Quinoline-Based P2-P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3\/4a Protease Inhibitors","volume":"5","author":"Shah","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4269\/ajtmh.1988.39.312","article-title":"A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection","volume":"39","author":"Quiroz","year":"1988","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_70","unstructured":"National Institute of Allergy and Infectious Diseases (2020, May 05). Antiretroviral Drug Discovery and Development, Available online: https:\/\/www.niaid.nih.gov\/diseases-conditions\/antiretroviral-drug-development."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/12\/2784\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:39:35Z","timestamp":1760175575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/12\/2784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":70,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["molecules25122784"],"URL":"https:\/\/doi.org\/10.3390\/molecules25122784","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]}}}